# hypo-FLAME 2.0 (NCT04045717)

> Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04045717
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Universitaire Ziekenhuizen KU Leuven
- Conditions: Prostate Adenocarcinoma; Prostate Cancer; Prostate Neoplasm
- Interventions: Hypo-FLAME 2.0 study
- Enrollment: 124
- Primary outcome: Acute toxicity

## Indexed commentary on hypo-FLAME 2.0 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=hypo-flame-2-0-nct04045717